TCR2 THERAPEUTICS Volatility Jumps to 7.85%: Prepare for the Unexpected
December 28, 2022
Trending News 🌥️
TCR2 THERAPEUTICS ($NASDAQ:TCRR) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel T cell therapies for patients suffering from cancer. The company is based in Cambridge, Massachusetts and is publicly traded on the Nasdaq Stock Exchange. Recently, TCR2 THERAPEUTICS has experienced a significant increase in volatility, with the stock jumping to 7.85%. This means that investors should be prepared for unexpected price changes in the near future. It is important to keep in mind that volatility can both increase and decrease depending on various factors such as news, market conditions, and economic performance. Volatility is often seen as a sign of potential risk for investors. As the stock price of TCR2 THERAPEUTICS increases, it could potentially lead to losses for those who bought at a higher price point.
On the other hand, it could also lead to potential gains for those who bought at a lower price point. In order to prepare for the unexpected, investors should do their own research and assess their own risk tolerance before investing in TCR2 THERAPEUTICS. It is also important to consider the overall market environment and any potential news that could affect the stock price. Investors should also watch out for any analysts’ reports or recommendations that may provide additional insight into the stock’s performance. Overall, investors should be aware of the increased volatility of TCR2 THERAPEUTICS and be prepared for any potential price changes that may come in the near future. By doing their own research and assessing their risk tolerance, they can make informed decisions when it comes to investing in this company.
Share Price
At the time of writing, media sentiment surrounding TCR2 Therapeutics appears mostly positive. On Tuesday, the stock opened at $0.8 and closed at $0.8, down by 1.9% from the previous closing price of 0.8. This means that TCR2 Therapeutics had a volatile day in the market with its volatility jumping to 7.85%. This surge in volatility indicates that investors should be prepared for the unexpected when it comes to TCR2 Therapeutics, and should be constantly monitoring news and developments in the company. Investors should also be aware of any potential changes in sentiment, as this could affect the stock price. Given the uncertainty surrounding the stock, investors should be sure to do their due diligence before making any investment decisions. This includes researching the company’s financials, management, and business model.
Additionally, investors should consider their risk tolerance and financial goals before investing in TCR2 Therapeutics or any other stocks. Overall, while TCR2 Therapeutics has seen a jump in volatility, investors should still remain aware of potential risks and rewards associated with investing in the stock. As such, they should remain vigilant and prepared for the unexpected when it comes to TCR2 Therapeutics. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tcr2 Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -99.81 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tcr2 Therapeutics. More…
| Operations | Investing | Financing |
| -81.6 | 78.45 | 132.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tcr2 Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 323.37 | 41.89 | 7.31 |
Key Ratios Snapshot
Some of the financial key ratios for Tcr2 Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -24.8% | -22.5% |
VI Analysis
TCR2 THERAPEUTICS Inc. is a medium risk investment according to the VI Risk Rating. This rating is based on the company’s financial and business fundamentals, which indicate its long-term potential. The VI App has detected four risk warnings in the company’s income sheet, balance sheet, cashflow statement and financial journal. Investors should be aware that TCR2 THERAPEUTICS Inc. may not be able to generate substantial profits or have sufficient capital to finance its operations. The company’s financial health may be weakened by a high debt burden or by inadequate cash flows. The balance sheet may also indicate other issues, such as the fact that the company is unable to generate enough revenue to cover its expenses. The income sheet can tell investors whether the company is able to generate sufficient revenue to cover its expenses, while the cashflow statement reveals whether the company has enough money to finance its operations. The financial journal can provide further insight into the company’s performance over time. In conclusion, TCR2 THERAPEUTICS Inc. is a medium risk investment according to the VI Risk Rating, and investors should pay close attention to the company’s financial and business fundamentals before making any decisions. By monitoring the income sheet, balance sheet, cashflow statement and financial journal, investors can get a better understanding of the company’s short and long-term prospects. More…
VI Peers
The company’s lead program is Tigatuzumab, which is in Phase II clinical trials for the treatment of solid tumors. TCR2 is also developing a pipeline of other T cell therapies with the potential to treat a range of cancers. TCR2’s main competitors are Brainstorm Cell Therapeutics Inc, Iovance Biotherapeutics Inc, and Immatics NV. These companies are also developing T cell therapies for the treatment of cancer.
– Brainstorm Cell Therapeutics Inc ($NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc is a biotechnology company that develops and commercializes adult stem cell therapies for neurodegenerative diseases. The company has a market cap of 59.84M and a ROE of -137.41%. Brainstorm Cell Therapeutics Inc was founded in 2004 and is headquartered in New York, New York.
– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of cancer immunotherapy products based on tumor-infiltrating lymphocytes (TIL). The company’s product candidates include LN-144, LN-145, LN-168, and LN-169. LN-144 is in Phase II clinical trials for the treatment of metastatic melanoma; LN-145 in Phase I/II clinical trials for the treatment of cervical, head and neck, and non-small cell lung cancers; LN-168 in Phase I/II clinical trials for the treatment of ovarian and gastric cancers; and LN-169 in Phase I/II clinical trials for the treatment of bladder cancer. Iovance Biotherapeutics was founded by Philip D. Gregory and Maria Fardis on October 3, 2011 and is headquartered in San Carlos, CA.
– Immatics NV ($NASDAQ:IMTX)
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the development of T cell-based immunotherapies for the treatment of cancer. The company’s product candidates include IMA901 that is in Phase II clinical trials for the treatment of solid tumors, as well as in Phase I/II trials for the treatment of acute myeloid leukemia and multiple myeloma; IMA950, which is in Phase I clinical trial for the treatment of pancreatic cancer; and IMA960, a preclinical stage product candidate for the treatment of glioblastoma. Immatics NV was founded in 1999 and is headquartered in Martinsried, Germany.
Summary
Investors in TCR2 Therapeutics should be prepared for potential volatility, as the stock price has recently jumped to 7.85%. At the time of writing, media sentiment towards the company appears to be mostly positive. An analysis of the company’s performance should take into account its financial statements, its market position, and the industry it operates in.
Further, investors should keep an eye on news and developments related to the company, and consider the performance of its peers in the industry. Ultimately, a thorough analysis of the company’s fundamentals is recommended before making any investment decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
